Sue Bazner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sue Bazner has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Eric S. Rosenberg
Massachusetts General Hospital, Boston, Massachusetts, USA
1 shared publication - Graham McGrath
Departments of Medicine and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
1 shared publication - Jenna Rychert
Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, MA, USA
1 shared publication - Lindsay Jones
Departments of Medicine and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 18 April 2013
- Published by Springer Nature in Virology Journal
- Vol. 10 (1) , 120
A monoclonal antibody against lymphocyte function-associated antigen-1 decreases HIV-1 replication by inducing the secretion of an antiviral soluble factor
Lymphocyte Function-Associated Antigen-1 (LFA-1) likely plays a role in the pathogenesis of against HIV-1 and is known to facilitate cell-to-cell transmission of the virus. A monoclonal antibody specific for LFA-1 (Cytolin®) was evaluated as a potential therapeutic in pilot studies performed in the mid-1990s. These uncontrolled human studies suggested that administration of this anti-LFA-1 antibody to HIV-1 infected individuals could provide a modest benefit by decreasing circulating HIV-1 RNA and increasing CD4+ T cell counts. At the time, it was proposed that when bound to cytolytic T cells, the antibody inhibited lysis of activated CD4+ T cells. Given the renewed interest in monoclonal antibody therapy for HIV-1 infected individuals, we investigated possible mechanisms of action of this antibody in vitro.
- 18 April 2013
- Published by Springer Nature in Virology Journal
- Vol. 10 (1) , 120
Open AccessA monoclonal antibody against lymphocyte function-associated antigen-1 decreases HIV-1 replication by inducing the secretion of an antiviral soluble factor
Lymphocyte Function-Associated Antigen-1 (LFA-1) likely plays a role in the pathogenesis of against HIV-1 and is known to facilitate cell-to-cell transmission of the virus. A monoclonal antibody specific for LFA-1 (Cytolin®) was evaluated as a potential therapeutic in pilot studies performed in the mid-1990s. These uncontrolled human studies suggested that administration of this anti-LFA-1 antibody to HIV-1 infected individuals could provide a modest benefit by decreasing circulating HIV-1 RNA and increasing CD4+ T cell counts. At the time, it was proposed that when bound to cytolytic T cells, the antibody inhibited lysis of activated CD4+ T cells. Given the renewed interest in monoclonal antibody therapy for HIV-1 infected individuals, we investigated possible mechanisms of action of this antibody in vitro.